Mark J Gergen Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark J Gergen.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark J Gergen. Mark J Gergen is Sr VP Corporate Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and Sr VP, Corporate Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and SVP Corporate Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and SVP, Corporate Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and SVP, Chief Operating Officer in HALOZYME THERAPEUTICS INC ($GYHT) and Executive VP, COO in Mirati Therapeutics, Inc. ($MYG) and President and CBO in Poseida Therapeutics, Inc. ($PSTX).
Latest Insider Trading Transactions of Mark J Gergen
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMLN, GYHT, MYG, PSTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 05 2021 | PSTX | Poseida Therapeuti ... | Gergen Mark J | President and CBO | Option Exercise | A | 9.15 | 342,000 | 3,129,300 | 342,000 | |
| Feb 05 2021 | PSTX | Poseida Therapeuti ... | Gergen Mark J | President and CBO | Option Exercise | A | 9.15 | 342,000 | 3,129,300 | 342,000 | |
| Jul 13 2020 | PSTX | Poseida Therapeuti ... | Gergen Mark J | President and CBO | Option Exercise | A | 16.00 | 75,000 | 1,200,000 | 75,000 | |
| Sep 02 2016 | GYHT | HALOZYME THERAPEUT ... | Gergen Mark J | SVP, Chief Operatin ... | Option Exercise | A | 9.97 | 333,890 | 3,328,883 | 333,890 | |
| Jan 26 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Option Exercise | A | 24.99 | 60,000 | 1,499,400 | 60,000 | |
| Jan 19 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Option Exercise | M | 8.50 | 10,000 | 85,000 | 117,000 | |
| Jan 19 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Option Exercise | M | 8.50 | 5,000 | 42,500 | 127,000 | |
| Jan 19 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Sell | S | 25.92 | 10,000 | 259,211 | 5,748 | 15.7 K to 5.7 K (-63.50 %) |
| Jan 19 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Buy | M | 8.50 | 10,000 | 85,000 | 15,748 | 5.7 K to 15.7 K (+173.97 %) |
| Jan 19 2016 | MYG | Mirati Therapeutic ... | Gergen Mark J | Executive VP, COO | Buy | M | 8.50 | 5,000 | 42,500 | 5,748 | 748 to 5.7 K (+668.45 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 0.00 | 25,000 | 0 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | H | 41.34 | 32,415 | 1,340,036 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | H | 36.90 | 57,289 | 2,113,964 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 24.87 | 65,980 | 1,640,923 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 18.01 | 63,252 | 1,139,169 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 16.54 | 2,956 | 48,892 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 16.02 | 91,621 | 1,467,768 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 15.03 | 62,467 | 938,879 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 9.02 | 51,561 | 465,080 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | H | 41.34 | 2,585 | 106,864 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | H | 36.90 | 2,711 | 100,036 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 24.87 | 4,020 | 99,977 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 18.01 | 6,748 | 121,531 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 16.80 | 23,064 | 387,475 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 16.54 | 344 | 5,690 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 16.02 | 8,379 | 134,232 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 15.03 | 7,533 | 113,221 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | J | 9.02 | 3,439 | 31,020 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 1,360 | 42,160 | 0 | 1.4 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 6,614 | 205,034 | 1,360 | 8 K to 1.4 K (-82.94 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 473 | 14,663 | 0 | 473 to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 2,136 | 66,216 | 473 | 2.6 K to 473 (-81.87 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | J | 31.00 | 53,181 | 1,648,611 | 0 | 53.2 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Buy | J | 31.00 | 53,181 | 1,648,611 | 53,181 | 0 to 53.2 K |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 412 | 12,772 | 0 | 412 to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | U | 31.00 | 64,338 | 1,994,478 | 412 | 64.8 K to 412 (-99.36 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 14.62 | 936 | 13,684 | 64,750 | 63.8 K to 64.8 K (+1.47 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 16.02 | 91,621 | 1,467,768 | 91,621 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 16.02 | 8,379 | 134,232 | 8,379 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 10,000 | 0 | 63,814 | 53.8 K to 63.8 K (+18.58 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | S | 17.11 | 1,846 | 31,585 | 53,814 | 55.7 K to 53.8 K (-3.32 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | S | 17.03 | 7,518 | 128,033 | 54,826 | 62.3 K to 54.8 K (-12.06 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 20,000 | 0 | 62,344 | 42.3 K to 62.3 K (+47.23 %) |
| Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Payment of Exercise | F | 16.47 | 3,133 | 51,601 | 42,344 | 45.5 K to 42.3 K (-6.89 %) |
| Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 8,000 | 0 | 45,477 | 37.5 K to 45.5 K (+21.35 %) |
| Jan 12 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 15,000 | 0 | 37,477 | 22.5 K to 37.5 K (+66.73 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 15.03 | 62,467 | 938,879 | 62,467 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 15.03 | 7,533 | 113,221 | 7,533 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 15,000 | 0 | 21,666 | 6.7 K to 21.7 K (+225.02 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Option Exercise | A | 18.01 | 63,252 | 1,139,169 | 63,252 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Option Exercise | A | 18.01 | 6,748 | 121,531 | 6,748 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Grant | A | 17.83 | 412 | 7,346 | 6,079 | 5.7 K to 6.1 K (+7.27 %) |
| Mar 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP Corporate Dev ... | Option Exercise | A | 9.02 | 51,561 | 465,080 | 81,561 | |
| Mar 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP Corporate Dev ... | Option Exercise | A | 9.02 | 30,000 | 270,600 | 30,000 | |
| Mar 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP Corporate Dev ... | Option Exercise | A | 9.02 | 3,439 | 31,020 | 3,439 | |
| Mar 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP Corporate Dev ... | Grant | A | 0.00 | 2,550 | 0 | 3,455 | 905 to 3.5 K (+281.77 %) |
| Feb 05 2009 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP Corporate Dev ... | Grant | A | 11.80 | 585 | 6,903 | 4,506 | 3.9 K to 4.5 K (+14.92 %) |
| Mar 06 2008 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | A | 24.87 | 65,980 | 1,640,923 | 65,980 | |
| Mar 06 2008 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | A | 24.87 | 4,020 | 99,977 | 4,020 | |
| Feb 05 2008 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Grant | A | 37.00 | 182 | 6,734 | 3,069 | 2.9 K to 3.1 K (+6.30 %) |
| Nov 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 18,436 | |
| Nov 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 44.00 | 500 | 22,000 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Nov 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Oct 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 18,936 | |
| Oct 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 50.00 | 500 | 25,000 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Oct 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Oct 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 19,436 | |
| Oct 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 49.83 | 500 | 24,915 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Oct 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 19,936 | |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 20,436 | |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 50.00 | 500 | 25,000 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 49.00 | 500 | 24,500 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Sep 06 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Aug 08 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 20,936 | |
| Aug 08 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 50.00 | 500 | 25,000 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Aug 08 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Aug 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 21,436 | |
| Aug 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 46.50 | 500 | 23,250 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Aug 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Jul 25 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 21,936 | |
| Jul 25 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 45.00 | 500 | 22,500 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Jul 25 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Jul 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 22,436 | |
| Jul 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 41.20 | 500 | 20,600 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Jul 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Jun 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 1,000 | 16,800 | 22,936 | |
| Jun 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 46.16 | 1,000 | 46,160 | 2,937 | 3.9 K to 2.9 K (-25.40 %) |
| Jun 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 1,000 | 16,800 | 3,937 | 2.9 K to 3.9 K (+34.05 %) |
| May 23 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 23,936 | |
| May 23 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 45.00 | 500 | 22,500 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| May 23 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| May 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 24,436 | |
| May 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 41.25 | 500 | 20,625 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| May 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Apr 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 24,936 | |
| Apr 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 37.47 | 500 | 18,735 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Apr 03 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Mar 09 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | A | 36.90 | 57,289 | 2,113,964 | 57,289 | |
| Mar 09 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | A | 36.90 | 2,711 | 100,036 | 2,711 | |
| Mar 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 25,436 | |
| Mar 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 37.75 | 500 | 18,875 | 2,937 | 3.4 K to 2.9 K (-14.55 %) |
| Mar 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,437 | 2.9 K to 3.4 K (+17.02 %) |
| Mar 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Grant | A | 33.07 | 340 | 11,245 | 2,937 | 2.6 K to 2.9 K (+13.09 %) |
| Feb 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 25,936 | |
| Feb 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 38.75 | 500 | 19,375 | 2,597 | 3.1 K to 2.6 K (-16.14 %) |
| Feb 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 3,097 | 2.6 K to 3.1 K (+19.25 %) |
| Feb 02 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Grant | A | 36.07 | 416 | 15,005 | 2,597 | 2.2 K to 2.6 K (+19.07 %) |
| Jan 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Option Exercise | M | 16.80 | 500 | 8,400 | 26,436 | |
| Jan 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Sell | S | 36.29 | 500 | 18,145 | 2,181 | 2.7 K to 2.2 K (-18.65 %) |
| Jan 04 2007 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | Sr VP, Corporate De ... | Buy | M | 16.80 | 500 | 8,400 | 2,681 | 2.2 K to 2.7 K (+22.93 %) |
Page: 1